Brief: Edesa Biotech Reports Additional Results From Phase 3 Paridiprubart Study
24/02/2026 14:16
Feb 24 (Reuters) - Edesa Biotech Inc EDSA.O: EDESA BIOTECH REPORTS ADDITIONAL POSITIVE RESULTS FROM PHASE 3 PARIDIPRUBART STUDY EDESA BIOTECH INC - REPORTS STATISTICALLY SIGNIFICANT MORTALITY REDUCTIONS IN 278 PATIENTS EDESA BIOTECH INC - PARIDIPRUBART REDUCES MORTALITY TO 15% IN NON-IMV PATIENTS EDESA BIOTECH INC: SAFETY PROFILE WAS CONSISTENT WITH PRIOR CLINICAL EXPOSURES, WITH MORE THAN 400 PATIENTS NOW HAVING RECEIVED PARIDIPRUBART EDESA BIOTECH INC - PARIDIPRUBART SHOWS 30% MORTALITY REDUCTION IN PNEUMONIA Source text: ID:nGNX4N2sTc Further company coverage: EDSA.O (((( Reuters.briefs@thomsonreuters.com ;));))